Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2011 - 2017)

Supernus Pharmaceuticals (SUPN) has 6 years of Current Deferred Revenue data on file, last reported at $287000.0 in Q4 2017.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $287000.0 in Q4 2017; TTM through Dec 2017 was $287000.0, a N/A change from a year earlier, with the FY2017 full-year figure at $287000.0, changed N/A from the prior year.
• Current Deferred Revenue for Q4 2017 stood at $287000.0, down from $1.3 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for SUPN reached as high as $1.6 million in Q4 2013 and fell as low as $100000.0 in Q2 2015.
• Historically, Current Deferred Revenue has averaged $937400.0 across 4 years, with a median of $1.3 million in 2015.
• Across the five-year window, Current Deferred Revenue surged 214.96% in 2013 and retreated 12.5% in 2014, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.6 million in 2013, then slipped by 12.5% to $1.4 million in 2014, then slipped by 7.14% to $1.3 million in 2015, then slumped by 77.92% to $287000.0 in 2017.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $287000.0 in Q4 2017, $1.3 million in Q3 2015, and $100000.0 in Q2 2015.